LOGIN  |  REGISTER
Viking Therapeutics
Chimerix

Alphatec to Participate in Upcoming Investor Conferences

July 24, 2023 | Last Trade: US$12.24 0.24 -1.92

CARLSBAD, Calif. / Jul 24, 2023 / Business Wire / Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor events:

  • The Canaccord Genuity Growth Conference in Boston, MA, on August 9, 2023, with a fireside chat at 10:30am ET
  • The Needham Virtual MedTech Conference on August 15, 2023
  • The RBC West Coast Medical Device Bus Tour on August 16, 2023, which will visit ATEC Headquarters at 9:30am PT
  • The Piper Sandler MedTech and Diagnostics California Bus Tour on August 22, 2023, with a fireside chat at 8:00am PT
  • The Morgan Stanley Global Healthcare Conference in New York, NY, on September 13, 2023, with a fireside chat at 10:10am ET
  • The Lake Street Capital Markets Best Ideas Growth Conference in New York, NY, on September 14, 2023

If available, webcasts of the conference presentations and archived recordings will be accessible from the Investor Relations Section of the Company’s website.

About ATEC

ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation MachineTM is focused on developing new approaches that integrate seamlessly with the Company’s expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC’s vision is to be the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.

Chimerix

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page